BioSphere Medical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioSphere Medical, Inc.
Medtech start-ups are taking on the global endometrial ablation and uterine artery embolization markets with next-generation systems designed to raise the standard of care in menorrhagia treatment. Profiles of Channel Medsystems, EmboMedics, and Minerva Surgical.
EmboMedics Inc. has developed a bioresorbable embolic bead technology to treat uterine fibroids without causing long-term side effects. Currently in preclinical testing, EmboMedics' technology will initially be used in the treatment of uterine fibroids, although its potential for controlled and predictable drug release could lend itself to a variety of other acute and chronic indications, including liver and prostate cancer, trauma, and obesity.
The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.
Current embolic therapies for cancer have one major drawback. When they're introduced into a vessel through a catheter, reflux often occurs along the catheter, sending the medication backward into another vessel and into non-targeted tissue. The safety of these could greatly improve with Surefire Medical's new embolic therapy catheter. Surefire's initial therapeutic target is liver cancer.